This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval
by Zacks Equity Research
Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.
Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs
by Zacks Equity Research
Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.
Here's What Could Help Bicycle Therapeutics PLC Sponsored ADR (BCYC) Maintain Its Recent Price Strength
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bicycle Therapeutics (BCYC) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Bicycle Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Bicycle Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Has Bicycle Therapeutics PLC Sponsored (BCYC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BCYC) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for March 16th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 16th.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Bicycle Therapeutics PLC Sponsored (BCYC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BCYC) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for March 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 13th